A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.
Also called NCT07219602
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT07219602
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Czechia, Netherlands, Slovakia
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07219602. Randomized; quadruple masking; primary purpose prevention. Start 2025-12-11 (actual); primary completion 2028-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
- Acronym
- RUBENS
- Condition
- Lipidemia
- Condition
- Type 2 Diabetes (T2DM)
- Condition
- Metabolic Syndrome (MetS)
- Intervention (Drug)
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- Intervention (Drug)
- Obicetrapib 10 mg
- Intervention (Other)
- Placebo
- Lead sponsor
- NewAmsterdam Pharma
Record details
- Record id
cardio:ct-nct07219602- Content hash
606aab18eba182a13db6babcc73adffd9b461d6128248f9f91146608603f5e70